This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Achillion's Uridine-Analog Nucleotide Prodrug, ACH-3422, Shows Compelling Preclinical Profile

NEW HAVEN, Conn., Nov. 2, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced a poster presentation detailing the preclinical profile of ACH-3422, a uridine-analog nucleotide prodrug being advanced for the potential treatment of chronic hepatitis C viral infection (HCV). The poster is being presented at the 64 th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2013) in Washington D.C.

The poster presentation, entitled, "Preclinical Characteristics of ACH-3422: A Potent Uridine Nucleotide Prodrug for Inhibition of Hepatitis C Virus NS5B RNA Polymerase," (Poster 475; HCV Therapy: The Developmental Pipeline. Saturday, November 2, 2013: 2:00 PM – 7:30 PM ET. Poster Hall), details the potent and specific inhibition of HCV NS5B polymerase by ACH-3422, and the demonstrated low risk for mitochondrial toxicity based upon in vitro studies with human cells in static and proliferating conditions, and high efficiency in the conversion of ACH-3422 into the triphosphate within human hepatocyte cell lines. These attributes, combined with the previously reported 14-day animal toxicity study of ACH-3422, continue to support the advancement of this compound toward clinical studies for use in combination with other direct acting antiviral agents for the potential pan-genotypic treatment of chronic HCV.

"These data provide additional insight into the compelling profile of ACH-3422 as a potential NS5B nucleotide inhibitor for the broad treatment of HCV. Based upon our current development timelines, we anticipate initiating our first-in-human and proof-of-concept trials with ACH-3422 during the first half of 2014," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "We believe that the ability to potentially combine a potent nucleotide, such as ACH-3422, with our other proprietary assets, including our differentiated Phase 2 NS5A inhibitor, ACH-3102, and our Phase 2 protease inhibitors, including ACH-2684, provides extensive optionality for developing a simple and effective all-oral treatment regimen aimed at curing HCV across broad treatment populations."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,111.93 +73.96 0.41%
S&P 500 2,112.70 +3.78 0.18%
NASDAQ 5,054.6440 -5.6020 -0.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs